Latest News and Press Releases

STOCKHOLM - November 20, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announces the inclusion of the first patient in a clinical Phase 2a...

STOCKHOLM - November 20, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, today announces the inclusion of the first patient in a clinical Phase 2a...

STOCKHOLM - November 9, 2017. Karolinska Development today announces that the company will receive 140,149 shares in Pharmanest AB. Furthermore, the company will receive 11,527 shares via KCIF...

STOCKHOLM den 9 november 2017. Karolinska Development meddelar idag att bolaget kommer att erhålla 140 149 aktier i Pharmanest AB samt ytterligare 11 527 aktier indirekt via KCIF Co-investment Fund...

STOCKHOLM 6 November 2017. Karolinska Development today announces that the company has sold 1.5 million shares to a total amount of SEK 35 million in the portfolio company BioArctic Neurosciences AB...

STOCKHOLM den 6. november 2017. Karolinska Development meddelar idag att man i samband med börsnoteringen av portföljbolaget BioArctic avyttrat 1,5 miljoner aktier till ett totalt belopp om 35...

Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048 ("Karolinska Development" eller "Bolaget"), kallas till extra bolagsstämma tisdagen den 28 november 2017 klockan 16.00 på...

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048 ("Karolinska Development" or the "Company") are invited to the Extraordinary General Meeting on Tuesday November 28, 2017...

STOCKHOLM - October 31, 2017. The number of series B shares in Karolinska Development AB (Nasdaq Stockholm: KDEV) has increased by 106 shares via conversion of convertible loans. Today, the last...

STOCKHOLM den 31 oktober 2017. Antalet aktier av Serie B i Karolinska Development AB (Nasdaq Stockholm: KDEV) har ökat med 106 genom konvertering av konvertibellån.Idag, den sista handelsdagen i...